ZAVICEFTA (ceftazidime–avibactam) is indicated for the treatment of adult and paediatric patients aged 3 months and older for the treatment of the following infections:1*Virkningsmekanisme
Complicated urinary tract infection (cUTI), including pyelonephritis
Hospital-acquired pneumonia, including ventilator-associated pneumonia (HAP/VAP)
Infections due to aerobic
Gram-negative organisms in patients with limited treatment options†
ZAVICEFTA is also indicated for the treatment of adult patients with bacteraemia that occurs in association with, or is suspected to be associated with, cUTI, cIAI or HAP/VAP
ZAVICEFTA is a combination of ceftazidime, an antipseudomonal cephalosporin, and avibactam, a β-lactamase inhibitor1–4
ZAVICEFTA mode of action1,5Ceftazidime
inhibits bacterial peptidoglycan cell wall synthesis following binding to PBPs, which leads to bacterial cell lysis and death.
is a non β-lactam, β-lactamase
Watch the below video to gain further insight into ZAVICEFTA’s mode of action1
inhibitor that acts by forming a covalent adduct with the enzyme that is stable to hydrolysis. It inhibits both Ambler class A and class C β-lactamases and some class D enzymes, including ESBLs, KPC and OXA-48 carbapenemases, and AmpC enzymes.
ZAVICEFTA has bactericidal activity against a broad-spectrum of resistant Gram-negative pathogens1–3
Combining ceftazidime and avibactam provides broad-spectrum Gram-negative coverage, including in vitro activity against1,2,6–8
ZAVICEFTA FOR PRECISE DESTRUCTION1,9Targeted efficacy against a broad range of MDR Gram-negative pathogens.1,2,6Explore moreClinical efficacy
Explore ZAVICEFTA’s clinical efficacy in cIAI, cUTI and HAP/VAP.
Learn more about ZAVICEFTA’s dosing in adult and paediatric patients.
Footnotes:*Consideration should be given to the official guidance on the appropriate use of antibacterial agents.1
†Data support the use of ZAVICEFTA in adult patients with limited treatment options including in primary bacteraemia, cSSTI, BJI, meningitis, febrile neutropenia, cystic fibrosis, post-transplant patients due to KPC and OXA-48 resistance mechanisms, and MDR Pseudomonas.10-24
‡Avibactam does not inhibit class B enzymes (metallo-β-lactamases) and is not able to inhibit many class D enzymes.Abbreviations:AmpC, ampicillinase C; BJI, bone and joint infection; cIAI, complicated intra-abdominal infection; cUTI, complicated urinary tract infection; cSSTI, complicated skin and soft-tissue infection; ESBL, extended-spectrum β-lactamase; HAP, hospital-acquired pneumonia; IDSA, Infectious Diseases Society of America; KPC, Klebsiella pneumoniae carbapenemase; MDR, multidrug-resistant; OXA, oxacillinase; PBP, penicillin binding proteins; VAP, ventilator-associated pneumonia.References:ZAVICEFTA. Summary of Product Characteristics, 2022.Liscio JL, et al. Int J Antimicrob Agents 2015;46:266–71.Nicolau DP, et al. J Antimicrob Chemother 2015;70:2862–9.Stone GG, et al. Antimicrob Agent Chemother 2020;64:e02356-19.Qin W, Panunzio M, Biondi S. Antibiotics (Basel) 2014;3:193–215Mazuski JE, et al. Surg Infect 2017;18:1–76.Pogue JM, et al. Clin Infect Dis 2019;68:519–24.Zhanel GG, et al. Drugs 2013;73:159–77.Zhang W, et al. Antimicrob Resist Infect Control 2018:7;142.Castón JJ, et al. Int J Infect Dis 2017;59:118–23.van Duin D, et al. Clin Infect Dis 2018;66:163–71.Sousa A, et al. J Antimicrob Chemother 2018;73:3170–5.Temkin E, et al. Antimicrob Agents Chemother 2017;61:e01964-16.Shields K, et al. Antimicrob Agents Chemother 2017;61:e00883-17.Tumbarello M, et al. Clin Infect Dis 2019;68:355–64.Tumbarello M, et al. Clin Infect Dis 2021;ciab176.Tsolaki V, et al. Antimicrob Agents Chemother 2020;64:e02320-19.Rathish B, et al. Cureus 2021;13:e13081.Jabbour J-F, et al. Curr Opin Infect Dis 2020;33:146–54.Chen W, et al. Ann Transl Med 2020;8:39.Atkin SD, et al. Infect Drug Resist 2018;11:1499–510.Aguado JM, et al. Transplant Rev (Orlando) 2018;32:36–57.Soriano A, et al. Infect Dis Ther 2021;1–46.Mazuski JE, et al. Infect Dis Ther 2021;1–16.